

after the case is closed, in accordance with the Records Disposition Authority NC1-204-95-1, or successor Records Disposition Authority.

All records within ECRD are maintained within the system while a clemency petition is pending and for fifteen years after the year in which the case was closed. Copies of all records pertaining to cases closed in the previous calendar year contained within the system are sent to NARA on an annual basis. OPA maintains legal custody of these records until fifteen years have elapsed, at which point the records within ECRD are destroyed and NARA becomes the legal custodian of the records. This change occurs in accordance with Records Disposition Authority DA-204-2011-0001 or successor Records Disposition Authority.

**SYSTEM MANAGER(S) AND ADDRESS:**

Pardon Attorney, Office of the Pardon Attorney, U.S. Department of Justice, Washington, DC 20530.

**NOTIFICATION PROCEDURE:**

Address inquiries to the Pardon Attorney, Office of the Pardon Attorney, U.S. Department of Justice, Washington, DC 20530, or e-mail inquiries to [USPardon.Attorney@usdoj.gov](mailto:USPardon.Attorney@usdoj.gov).

**RECORD ACCESS PROCEDURES:**

The Attorney General has exempted executive clemency records from various provisions of the Privacy Act, including the access and amendment provisions, to the extent such exemptions apply pursuant to 5 U.S.C. 552a(j)(2). Where compliance would not appear to interfere with or adversely affect the purposes of the system or the law enforcement process, the applicable exemption (in whole or in part) may be waived by the OPA in its sole discretion. These requests for discretionary releases of records shall be made either in writing or via email to the system manager listed above with the envelope and letter or subject line clearly marked "Privacy Access Request." Include in the request the general subject matter of the document. Provide full name, current address, date and place of birth, signature, all of (which must be either be notarized or submitted under penalty of perjury), and a return address or email address for transmitting the information.

**CONTESTING RECORD PROCEDURES:**

Same as Record Access Procedures.

**RECORD SOURCE CATEGORIES:**

Sources of information include: individual applicants for clemency, their representatives, and persons who

write, confer with, or orally advise OPA concerning those applicants; investigatory reports of the Federal Bureau of Investigation, the Drug Enforcement Administration, the Internal Revenue Service, Immigration and Customs Enforcement agency of the Department of Homeland Security and other appropriate government agencies; records of the Federal Bureau of Prisons; reports of the Armed Forces; presentence reports provided by the Bureau of Prisons or the federal Probation Offices; reports of the U.S. Parole Commission; data provided by the Office of White House Counsel; comments and recommendations from current and former federal and state officials; and employees of the Department of Justice.

**EXEMPTIONS CLAIMED FOR THE SYSTEM:**

The Attorney General has exempted this system from subsections (c)(3), (c)(4), (d)(1), (d)(2), (d)(3), (d)(4), and (e)(5) of the Privacy Act pursuant to 5 U.S.C. 552a(j)(2). Rules have been promulgated in accordance with the requirements of 5 U.S.C. 553 (b), (c), and (e) and have been published in the **Federal Register**.

[FR Doc. 2011-23599 Filed 9-14-11; 8:45 am]

**BILLING CODE 4410-29-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Registration**

By Notice dated June 7, 2011, and published in the **Federal Register** on June 16, 2011, 76 FR 35239, Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by letter to the Drug Enforcement Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance in bulk for the manufacture of a controlled substance.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Noramco Inc. to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Noramco Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection

and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.

Dated: September 9, 2011.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2011-23620 Filed 9-14-11; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 3, 2011, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II.

The company plans to manufacture small quantities of the above listed controlled substance for distribution to its customers for the purpose of research.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than November 14, 2011.

Dated: September 9, 2011.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2011-23617 Filed 9-14-11; 8:45 am]

**BILLING CODE 4410-09-P**